A Phase Ib/II Study of BGJ398 in Combination Modified FOLFIRINOX in Treatment-Naïve Metastatic Pancreatic Cancer Patients
Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 30 May 2016
At a glance
- Drugs Infigratinib (Primary) ; Fluorouracil; Irinotecan
- Indications Adenocarcinoma; Colon cancer; Pancreatic cancer; Rectal cancer
- Focus Adverse reactions; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 19 May 2016 Status changed from not yet recruiting to withdrawn prior to enrolment due to drug supply issues.
- 29 Feb 2016 Planned initiation date changed from 1 Feb 2016 to 1 Mar 2016, according to ClinicalTrials.gov record.